HyperSight CBCT approached simulation-CT dosimetry for offline adaptive breast radiotherapy
HyperSight reduced PTV dose-recalculation deviations versus Halcyon 3.1 while using a lower imaging dose in 12 breast radiotherapy patients.
HyperSight reduced PTV dose-recalculation deviations versus Halcyon 3.1 while using a lower imaging dose in 12 breast radiotherapy patients.
Maskless SGRT reduced initial setup error and cut mean positioning time by about 29% compared with thermoplastic-mask alignment.
Whole-lung, physical-dose and BED3 models performed similarly externally, with the best complete-model AUC only 0.684 and inadequate calibration.
Voxel-wise cumulative EQD2 review prompted reoptimization in 25.5% of proton reirradiation courses and exposed frequent registration problems.
A 2D antiscatter grid reduced soft-tissue CT-number error from 169 to 38 HU at unchanged imaging dose.
A circulation-based model predicted post-SBRT lymphocyte trajectories and linked a higher predicted lymphocyte nadir with better survival.
Daily surface changes shifted proton beam depth by up to 17.4 mm and reduced accumulated target D99 by up to 24.3%.
VMAT-TBI achieved 96.6% mean PTV D95 while keeping mean lung and kidney doses below 9 Gy.
Planning on selected respiratory phases reduced lung, heart and esophageal dose, but the optimal phase differed by toxicity endpoint.
Only 10.7% of T2 MRI radiomics features remained highly stable across fat-saturation protocols, and stability filtering improved prediction.
More accurate deformable registration lowered estimated bowel dose, but produced nearly identical in-treatment adaptation decisions to simple DVH summation.
PATLESL increased lattice peak-to-valley dose ratio from 16.9 to 41.9 while reducing spot number and delivery time.
Energy-layer-wise compensation restored millimetre-level proton targeting despite magnetic-field beam shifts approaching 30 mm in an MR-integrated prototype.
The pre-plateau modulation factor preserved plan quality while further reduction created idle delivery time without meaningful efficiency gain.
CyberKnife best contained low-dose spread at high lesion burdens but required substantially longer treatment than faster VMAT strategies.